For example, GLP-1R agonists were able to improve glucose metabolism function through the GLP-1R/SIRT1/GLUT4 pathway in an AD model (Wang Z. J. et al., 2023), suggesting that GLP-1R may influence AD progression by modulating metabolic pathways associated with DM. This evidence concerns the gene SIRT1 and Alzheimer disease.